TrovaGene, Inc. (NASDAQ:TROV)

About the company

Trovagene, Inc. is a clinical-stage, precision cancer medicine oncology therapeutics company, which engages in the development of drugs that target cell division (mitosis), for the treatment of various cancers including leukemia, lymphomas, and solid tumors. The company was founded by Gabriel M. Cerrone, L. David Tomei, Samuil Umansky, and Hovsep Melkonyan on August 4, 1999 and is headquartered in San Diego, CA.

Sector

Health Services

Industry

Medical and Nursing Services

Employees

14

CEO

Thomas H. Adams

Exchange

NASDAQ

Website

http://www.trovagene.com

$0.00M

Total Revenue

14

Employees

$8.04M

Market Capitalization

-0.48

Price/Earning ratio

Stock price

Gross Margin (in %)

Total gross margin

Operating Margin (in %)

Total operating margin

Net Margin (in %)

Total net margin

Dividend Yield (in %)

Dividend per share

$0

Industry peers

Name Ticker Market capitalization (in USD Million) Revenues (in USD Million) Price/Book Price/Earning Net margin (in %)
DaVita, Inc. DVA 11671.20 11487.00 5.07 12.95 7.85
Chemed Corp. CHE 8152.35 1992.00 11.13 34.28 11.60
Guardant Health, Inc. GH 7931.04 245.00 10.74 -102.75 -31.53
Amedisys, Inc. AMED 6856.41 1980.00 9.90 53.97 6.43
LHC Group, Inc. LHCG 5555.20 2091.00 3.96 56.53 4.73
1Life Healthcare, Inc. ONEM 4746.42 292.00 10.21 -59.79 -27.31
NeoGenomics, Inc. NEO 3683.50 419.00 7.55 868.75 0.82
Natera, Inc. NTRA 3441.22 330.00 14.33 -27.73 -38.27
SmileDirectClub, Inc. SDC 3207.05 769.00 10.16 -26.03 -16.02
Invitae Corp. NVTA 3189.12 241.00 12.73 -10.45 -125.90
The Ensign Group, Inc. ENSG 2416.40 2155.00 3.43 19.52 5.76
Acadia Healthcare Co., Inc. ACHC 2311.76 3130.00 0.95 20.52 3.61
MEDNAX, Inc. MD 1449.18 3508.00 1.00 -1.14 -36.30
Addus HomeCare Corp. ADUS 1274.98 598.00 3.01 61.95 3.33
U.S. Physical Therapy, Inc. USPH 1056.38 478.00 4.33 35.96 6.03
RadNet, Inc. RDNT 778.50 1164.00 6.36 389.25 0.18
Castle Biosciences, Inc. CSTL 675.07 61.00 8.75 661.83 9.75
Option Care Health, Inc. OPCH 616.80 2539.00 2.61 -6.30 -3.63
The Pennant Group, Inc. PNTG 599.76 352.00 7.85 142.80 1.19
Hanger, Inc. HNGR 590.90 1095.00 -37.02 31.73 1.71
Tivity Health, Inc. TVTY 557.76 1255.00 72.62 -1.12 -38.98
Catasys, Inc. CATS 441.15 41.00 -16.12 -14.18 -74.67
Fulgent Genetics, Inc. FLGT 366.60 35.00 4.89 -1833.00 -1.31
OptiNose, Inc. OPTN 237.79 37.00 7.18 -2.16 -295.66
American Renal Associates Holdings, Inc. ARA 212.16 824.00 -2.63 -11.84 -2.19
Aptinyx, Inc. APTX 170.28 4.00 1.76 -3.05 -810.48
CRH Medical Corp. CRHM 167.17 117.00 2.20 114.50 1.52
Exagen, Inc. XGN 147.42 41.00 2.84 -4.61 -76.21
Pro-Dex, Inc. PDEX 71.16 31.00 3.95 16.17 14.50
Guardion Health Sciences, Inc. GHSI 35.70 1.00 2.62 -1.56 -824.43
Cardiff Oncology, Inc. CRDF 34.02 0.00 15.68 -2.22 -883.77
Biocept, Inc. BIOC 29.07 6.00 4.50 -1.06 -463.58
OncoSec Medical, Inc. ONCS 25.61 None 2.10 -0.68 None
Capital Senior Living Corp. CSU 19.20 439.00 -0.61 -0.28 -16.00
American Shared Hospital Services AMS 13.08 20.00 0.48 54.50 1.28
IMAC Holdings, Inc. IMAC 11.34 16.00 1.30 -1.68 -42.30
TrovaGene, Inc. TROV 8.04 0.00 2.03 -0.48 -883.77

Latest insider transactions

Date Role Name Transaction Quantity Quantity Owned After

Trovagene: 1Q Earnings Snapshot

2mon ago, source: The Register Citizen

Trovagene: 1Q Earnings Snapshot Published 5:23 am EDT, Friday, May 8, 2020 SAN DIEGO (AP) _ Trovagene Inc. (TROV) on Thursday reported a loss of $4.1 million in its first quarter.

Cardiff Oncology Raises $13.5M in Equity Funding

20d ago, source: finsmes.com

Led by Dr. Mark Erlander, Chief Executive Officer, Cardiff Oncology (formerly Trovagene, Inc.) is a clinical-stage oncology therapeutics company developing drugs to treat cancers with the greatest ...

Trovagene Announces Three New Nominees for Election to Board of Directors

20d ago, source: Bloomberg

Before it's here, it's on the Bloomberg Terminal.

Cardiff Oncology Secures $13.5 Million Equity Investment from Biotech-Focused Fundamental Institutional Investors Acorn Bioventures and CAM Capital

22d ago, source: YAHOO!

About Cardiff Oncology, Inc. Cardiff Oncology (formerly Trovagene, Inc.) is a clinical-stage biotechnology company with the singular mission of developing new treatment options for cancer patients ...

Cell-free DNA Testing Market Growth Analysis By Size, Share, News, Demand, Opportunity During 2020-2023

15d ago, source: MarketWatch

Jun 22, 2020 (AmericaNewsHour) -- Global Cell-free DNA Testing Market will multiply at impressive CAGR of 26.5% by 2023 & Top Key Players are ...

Cardiff Oncology Inc

1mon ago, source: Reuters

May 13 (Reuters) - Cardiff Oncology Inc <CRDF.O>::CARDIFF ONCOLOGY ENTERS AGREEMENT WITH POC CAPITAL TO FUND PHASE 2 CLINICAL TRIAL OF ONVANSERTIB IN KRAS-MUTATED METASTATIC COLORECTAL CANCER ...

CRDF Cardiff Oncology, Inc. Common Stock

23d ago, source: Nasdaq

Sign up for our newsletter to get the latest on the transformative forces shaping the global economy, delivered every Thursday.



Portfolio items

Follow companies to create your optimal portfolio.
or
Refresh this page to see your newly added stocks.